MA34910B1 - Dérivés de 2-methoxy-pyridin-4-yl - Google Patents

Dérivés de 2-methoxy-pyridin-4-yl

Info

Publication number
MA34910B1
MA34910B1 MA36184A MA36184A MA34910B1 MA 34910 B1 MA34910 B1 MA 34910B1 MA 36184 A MA36184 A MA 36184A MA 36184 A MA36184 A MA 36184A MA 34910 B1 MA34910 B1 MA 34910B1
Authority
MA
Morocco
Prior art keywords
pyridin
methoxy
derivatives
compounds
immunomodulators
Prior art date
Application number
MA36184A
Other languages
English (en)
Inventor
Martin Bolli
Cyrille Lescop
Boris Mathys
Keith Morrison
Claus Mueller
Oliver Nayler
Beat Steiner
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45607310&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34910(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA34910B1 publication Critical patent/MA34910B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'INVENTION CONCERNE DES DÉRIVÉS DE PYRIDINE REPRÉSENTÉS PAR LA FORMULE (I), DANS LAQUELLE A, R1, R2, R3 ET R4 SONT TELS QUE DÉFINIS DANS LA DESCRIPTION, LEUR PRÉPARATION ET LEUR UTILISATION EN TANT DE COMPOSÉS PHARMACEUTIQUEMENT ACTIFS. LES COMPOSÉS AGISSENT EN PARTICULIER EN TANT QU'AGENTS IMMUNOMODULATEURS
MA36184A 2011-01-19 2012-01-18 Dérivés de 2-methoxy-pyridin-4-yl MA34910B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2011050241 2011-01-19
PCT/IB2012/050241 WO2012098505A1 (fr) 2011-01-19 2012-01-18 Dérivés de 2-methoxy-pyridin-4-yl

Publications (1)

Publication Number Publication Date
MA34910B1 true MA34910B1 (fr) 2014-02-01

Family

ID=45607310

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36184A MA34910B1 (fr) 2011-01-19 2012-01-18 Dérivés de 2-methoxy-pyridin-4-yl

Country Status (28)

Country Link
US (1) US9133179B2 (fr)
EP (1) EP2665720B1 (fr)
JP (1) JP5859570B2 (fr)
KR (1) KR101869120B1 (fr)
CN (1) CN103313981B (fr)
AR (1) AR084883A1 (fr)
AU (1) AU2012208325B2 (fr)
BR (1) BR112013017923B1 (fr)
CA (1) CA2818470C (fr)
CL (1) CL2013002056A1 (fr)
CY (1) CY1116657T1 (fr)
DK (1) DK2665720T3 (fr)
ES (1) ES2544086T3 (fr)
HK (1) HK1191645A1 (fr)
HR (1) HRP20150919T1 (fr)
HU (1) HUE026012T2 (fr)
IL (1) IL227509A0 (fr)
MA (1) MA34910B1 (fr)
MX (1) MX350009B (fr)
MY (1) MY163185A (fr)
PL (1) PL2665720T3 (fr)
PT (1) PT2665720E (fr)
SG (1) SG191742A1 (fr)
SI (1) SI2665720T1 (fr)
TW (1) TWI546300B (fr)
UA (1) UA109804C2 (fr)
WO (1) WO2012098505A1 (fr)
ZA (1) ZA201306193B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ713080A (en) 2013-03-15 2020-06-26 Idorsia Pharmaceuticals Ltd Pyridin-4-yl derivatives
EP2990055B1 (fr) 2013-04-26 2019-06-05 Kyoto University Composition comprenant un agoniste du récepteur 1 de la sphingosine-1-phosphate pour empêcher la formation et/ou l'expansion d'un anévrisme cérébral ou pour réduire un tel anévrisme
CN105760707B (zh) * 2014-12-18 2018-07-31 中国科学院大连化学物理研究所 细胞基因翻译过程建模方法
HUE047646T2 (hu) * 2015-05-20 2020-05-28 Idorsia Pharmaceuticals Ltd Az (S)-3-{4-[5-(2-ciklopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi} -propán-1,2-diol vegyület kristályformája
CN107382965A (zh) * 2017-08-14 2017-11-24 河南科技大学第附属医院 具有抗肿瘤活性的新型s1p‑1受体激动剂药物分子的合成方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647809A (en) 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
AU7686891A (en) 1990-04-05 1991-10-30 American National Red Cross, The A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
ZA917371B (en) 1990-09-20 1992-06-24 Merrell Dow Pharma Calcium uptake inhibitors
DE4429465A1 (de) 1994-08-19 1996-02-22 Bayer Ag Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde
US6423508B1 (en) 1998-03-09 2002-07-23 Smithkline Beecham Corporation Polynucleotide sequences of human EDG-1c
DE19904389A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
NZ517221A (en) 1999-08-19 2004-01-30 Nps Pharma Inc Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
MXPA03007513A (es) 2001-02-21 2004-07-30 Nps Pharma Inc Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
EP1470137B1 (fr) 2002-01-18 2009-09-02 Merck & Co., Inc. Agonistes du recepteur edg
JP4709488B2 (ja) 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
WO2003105771A2 (fr) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates et 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates utilises en tant qu'agonistes du recepteur edg
DE10237883A1 (de) 2002-08-19 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
WO2004035538A1 (fr) 2002-10-15 2004-04-29 Merck & Co., Inc. Procede de fabrication de l'acide azetidine-3-carboxylique
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
US20060252741A1 (en) 2003-05-15 2006-11-09 Colandrea Vincent J 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
TW200505416A (en) 2003-08-12 2005-02-16 Mitsubishi Pharma Corp Bi-aryl compound having immunosuppressive activity
CN1859908A (zh) 2003-10-01 2006-11-08 默克公司 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
CA2547198A1 (fr) 2003-12-17 2005-06-30 Merck & Co., Inc. Carboxylates propanoiques 3,4-disusbstitues utilises en tant qu'agonistes du recepteur s1p (edg)
MXPA06013912A (es) 2004-05-29 2007-07-18 7Tm Pharma As Ligandos del receptor de crth2 para usos medicinales.
WO2006010379A1 (fr) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Nouveaux derives du thiophene utilises comme agents immunosupresseurs
WO2006047195A2 (fr) 2004-10-22 2006-05-04 Merck & Co., Inc. Carboxylates, sulfonates, phosphonates, phosphinates 2-(aryl)azacyclylmethyle et heterocycles utilises comme agonistes des recepteurs s1p
JP4318087B2 (ja) 2004-12-13 2009-08-19 小野薬品工業株式会社 アミノカルボン酸誘導体およびその医薬用途
PL1863474T3 (pl) 2005-03-23 2009-04-30 Actelion Pharmaceuticals Ltd Nowe pochodne tiofenu jako agoniści receptora 1 1-fosforanu sfingozyny
WO2006100635A2 (fr) 2005-03-23 2006-09-28 Actelion Pharmaceuticals Ltd Nouveaux derives de thiophene
BRPI0609515A8 (pt) 2005-03-23 2017-12-26 Actelion Pharmaceuticals Ltd Composto, composição farmacêutica, e, uso de um composto
WO2006108103A1 (fr) 2005-04-05 2006-10-12 Pharmacopeia, Inc. Derives de purine et d'imidazopyridine en vue d'une immunosuppression
WO2006115188A1 (fr) 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited Compose heterocyclique
AU2006239418A1 (en) 2005-04-26 2006-11-02 Neurosearch A/S Novel oxadiazole derivatives and their medical use
CA2610310A1 (fr) 2005-06-08 2006-12-14 Novartis Ag Oxadiazoles polycycliques ou soxazoles i et leur utilisation comme ligands recepteurs de s1p
WO2006135694A2 (fr) 2005-06-10 2006-12-21 Acadia Pharmaceuticals Inc. Composes modulateurs d'uii et utilisation
CA2612661A1 (fr) 2005-06-24 2006-12-28 Actelion Pharmaceuticals Ltd. Nouveaux derives de thiofene
WO2007001973A1 (fr) 2005-06-28 2007-01-04 Astrazeneca Ab Utilisation
AR057894A1 (es) 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
TWI404706B (zh) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
ES2335242T3 (es) 2006-01-24 2010-03-23 Actelion Pharmaceuticals Ltd. Derivados novedosos de piridina.
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
RU2008137553A (ru) 2006-02-21 2010-03-27 Юниверсити Оф Вирджиния Пэтент Фаундейшн (Us) Фенил-циклоалкильные соединения, содержащие гетероциклические структуры
CA2651629A1 (fr) 2006-05-09 2007-11-22 Pfizer Products Inc. Derives d'acide cycloalkylamine et compositions pharmaceutiques a base de ceux-ci
TWI408139B (zh) 2006-09-07 2013-09-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
TWI392671B (zh) 2006-09-07 2013-04-11 Actelion Pharmaceuticals Ltd 吡啶-４-基衍生物
PL2069335T3 (pl) 2006-09-08 2013-05-31 Actelion Pharmaceuticals Ltd Pochodne pirydyn-3-ylu jako środki immunomodulujące
ES2393412T3 (es) 2006-09-21 2012-12-21 Actelion Pharmaceuticals Ltd. Derivados de fenilo y su uso como inmunomoduladores
EP2081916A1 (fr) 2006-09-29 2009-07-29 Novartis AG Dérivés d'oxadiazole ayant des propriétés anti-inflammatoires et immuno-suppressives
JP2008120794A (ja) 2006-10-16 2008-05-29 Daiichi Sankyo Co Ltd ヘテロ環化合物を含有する医薬組成物
US20110207704A1 (en) 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
NZ577111A (en) 2006-12-15 2012-05-25 Abbott Lab Novel oxadiazole compounds
WO2008091967A1 (fr) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Composés chimiques
DK2125797T3 (da) 2007-03-16 2014-02-10 Actelion Pharmaceuticals Ltd Aminopyridinderivater som s1p1/edg1-receptoragonister
WO2009024905A1 (fr) 2007-08-17 2009-02-26 Actelion Pharmaceuticals Ltd Dérivés pyridiniques utilisés comme modulateurs du récepteur s1p1/edg1
CN104478821B (zh) 2007-10-04 2016-09-28 默克雪兰诺有限公司 噁二唑二芳基化合物
EA201070422A1 (ru) 2007-10-04 2010-12-30 Мерк Сероно С.А. Производные оксадиазола
AU2008320374A1 (en) 2007-11-01 2009-05-07 Actelion Pharmaceuticals Ltd Novel pyrimidine derivatives
CA2703987A1 (fr) 2007-11-08 2009-05-14 Pfizer Inc. Derives d'acide cyclobutylcarboxylique
WO2009074950A2 (fr) 2007-12-10 2009-06-18 Actelion Pharmaceuticals Ltd Nouveaux dérivés du thiophène
EP2222668B1 (fr) * 2007-12-18 2011-11-02 Arena Pharmaceuticals, Inc. Dérivés d'acide tétrahydrocyclopenta[b]indol-3-ylcarboxylique utiles dans le traitement de troubles auto-immuns et inflammatoires
JP5411877B2 (ja) 2008-03-06 2014-02-12 アクテリオン ファーマシューティカルズ リミテッド ピリジン化合物
WO2009109907A1 (fr) 2008-03-06 2009-09-11 Actelion Pharmaceuticals Ltd Nouveaux dérivés de pyrimidine-pyridine
EP2262782B1 (fr) * 2008-03-07 2012-07-04 Actelion Pharmaceuticals Ltd. Nouveaux dérivés d'aminométhylbenzène
KR101615779B1 (ko) 2008-03-07 2016-04-26 액테리온 파마슈티칼 리미티드 면역조절제로서 피리딘-2-일 유도체
PT2291080E (pt) 2008-05-14 2015-10-30 Scripps Research Inst Novos modelamodeladores dos recetores da esfingosina fosfato
TW201107302A (en) 2009-06-26 2011-03-01 Glaxo Group Ltd Compounds
RU2547098C2 (ru) * 2009-07-16 2015-04-10 Актелион Фармасьютиклз Лтд Производные пиридин-4-ила

Also Published As

Publication number Publication date
HRP20150919T1 (hr) 2015-09-25
SG191742A1 (en) 2013-08-30
TW201309681A (zh) 2013-03-01
WO2012098505A1 (fr) 2012-07-26
MY163185A (en) 2017-08-15
KR20140014128A (ko) 2014-02-05
PT2665720E (pt) 2015-09-16
RU2013138285A (ru) 2015-02-27
BR112013017923A2 (pt) 2017-03-21
BR112013017923B1 (pt) 2021-08-10
EP2665720B1 (fr) 2015-06-10
SI2665720T1 (sl) 2015-08-31
US20130303514A1 (en) 2013-11-14
JP2014502994A (ja) 2014-02-06
IL227509A0 (en) 2013-09-30
HUE026012T2 (en) 2016-05-30
ZA201306193B (en) 2016-07-27
CL2013002056A1 (es) 2013-12-27
EP2665720A1 (fr) 2013-11-27
MX350009B (es) 2017-08-23
CA2818470A1 (fr) 2012-07-26
PL2665720T3 (pl) 2015-11-30
ES2544086T3 (es) 2015-08-27
US9133179B2 (en) 2015-09-15
UA109804C2 (xx) 2015-10-12
CN103313981A (zh) 2013-09-18
BR112013017923A8 (pt) 2017-12-26
TWI546300B (zh) 2016-08-21
CY1116657T1 (el) 2018-04-04
MX2013007726A (es) 2013-08-09
HK1191645A1 (en) 2014-08-01
CN103313981B (zh) 2016-05-11
AR084883A1 (es) 2013-07-10
JP5859570B2 (ja) 2016-02-10
DK2665720T3 (en) 2015-07-13
NZ614367A (en) 2015-02-27
KR101869120B1 (ko) 2018-06-19
AU2012208325A1 (en) 2013-09-05
CA2818470C (fr) 2019-03-05
AU2012208325B2 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA35451B1 (fr) Dérivés de pyrrolopyrimidine et de purine
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MA35841B1 (fr) Dérivés de pyrazolopyridine, procédé d'élaboration de ces dérivés, et utilisation thérapeutique de ceux-ci
EA200870423A1 (ru) Производные триазолпиразинов, применимые в качестве противораковых агентов
MA37519B1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
MA31741B1 (fr) Derives fongicides de 2-alkylthio-2-quinolinyloxy- acetamide
MA33528B1 (fr) Derives pyridin-4-yliques
MA31849B1 (fr) Nouveaux dérivés de pyrimidine
MA35833B1 (fr) Dérivés de bétuline
MA34078B1 (fr) Derives d'arylethynyle
MA32173B1 (fr) Derives de pyridin-2-yle utilises comme agents immunomodulateurs
MA35086B1 (fr) Compose de triazolopyridine
TN2016000014A1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
MA34910B1 (fr) Dérivés de 2-methoxy-pyridin-4-yl
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
MA38555A1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'agonistes du récepteur cb2
MA34094B1 (fr) Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2
MA38679A1 (fr) Modulateurs du récepteur de cxcr7